XML 57 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Debt (Details Narrative)
Apr. 08, 2021
USD ($)
$ / shares
shares
Common stocks issued | shares 26,042
Common stock Exercise price | $ / shares $ 14.40
Debt issuance costs $ 500,000
Lendor [Member]  
Agreed to pay loan 25,000,000
Security and Loan agreement [Member] | Innovatus Life Sciences [Member]  
Term B loan to be funded before March 31, 2022 5,000,000
Non contingent term A loan, funded 15,000,000.0
Line of credit faciltiy, maximum borrowing capacity 25,000,000
Term C loan to be funded before March 31, 2023 $ 5,000,000
Common stock shares issuable upon exercise of warrants | shares 26,042
Additional debt discount recognized $ 300,000
Term loans, interest rate 11.36%
Term loans, interest, payable in kind 2.7%
Non refundable facility fee payable to lender, percentage 1.00%
Final fee payable to lender, percentage 4.50%
Non refundable facility fee payable to lender, amount $ 700,000
Final fee payable to lender, amount $ 100,000